Tff Pharmaceuticals, Inc. Stock News

TFF Pharmaceuticals, Inc. (NASDAQ:TFFP ) Q3 2022 Earnings Conference Call November 14, 2022 5:00 PM ET Company Participants Corey Davis - LifeSci Advisors Glenn Mattes - President, CEO & Director Dale

FORT WORTH, Texas, Sept. 06, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug pr

While the company added three more big pharma partners, this is not what shareholders prefer to hear as the company already has more than two dozen of these. These partnerships are mostly in the pre-c

Once promising, TFF Pharma is now cash-strapped and stagnant. TFFP badly needs some good news.

TFFP is a platform company with leading technology. Clinical/FDA risk is extremely low.

FORT WORTH, Texas, May 20, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug prod

TFF Pharmaceuticals, Inc. (NASDAQ:TFFP ) Q1 2022 Earnings Conference Call May 11, 2022 4:30 PM ET Company Participants Corey Davis - LifeSci Advisors Glenn Mattes - President, CEO & Director Kirk Cole

TFF Pharmaceuticals, Inc. (TFFP) delivered earnings and revenue surprises of 13.16% and 33%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Company conference call and webcast at 4:30 PM ET Company conference call and webcast at 4:30 PM ET

TFF Pharmaceuticals, Inc. (TFFP) CEO Glenn Mattes on Q4 2021 Results - Earnings Call Transcript

TFF Pharmaceuticals, Inc. (TFFP) delivered earnings and revenue surprises of -33.33% and 98.72%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the

TFF Pharmaceuticals Inc (NASDAQ: TFFP) has entered into a Cooperative Research and Development Agreement (CRADA) with the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) for d

Company conference call and webcast at 4:30 PM ET Company conference call and webcast at 4:30 PM ET

TFF Pharmaceuticals is on the hunt for new partners, and a recently-announced agreement with Catalent could help them land just that. The two companies announced a collaboration focused on the generation, testing and manufacture of dry powder formulations Tuesday. Thin film freezing is a platform technology that works on both

TFF Pharmaceuticals (TFFP) and Catalent (CTLT) are collaborating on the testing and manufacture of dry powder formulations for a range of biotherapeutics through the application of…